LEF1 Transcription Factor Identified as Master Regulator of T Cell Stemness in Chronic Disease
Researchers discover LEF1 marks true self-renewing T cells in autoimmunity and chronic infection, opening new therapeutic targets.
Summary
Scientists at Memorial Sloan Kettering have identified LEF1, a transcription factor, as the defining marker of true stem-like T cells that sustain immune responses in chronic diseases like type 1 diabetes and chronic infections. Previously, TCF1 was considered the key marker, but this research reveals that only a small subset of TCF1-high T cells that also express LEF1 are genuinely self-renewing. These stem T cells follow a hierarchy: LEF1-positive stem cells give rise to progenitor cells, which then produce terminally differentiated cells that lose stemness. Importantly, LEF1-positive T cells share an epigenetic program with embryonic stem cells, involving WNT and Notch signaling pathways. Blocking integrin or Notch signals disrupted T cell stemness and prevented disease in preclinical models, suggesting promising new therapeutic strategies.
Detailed Summary
Chronic diseases driven by persistent immune activation — including autoimmune conditions and chronic infections — depend on a reservoir of stem-like T cells capable of long-term self-renewal. Understanding what truly defines these cells is critical for developing therapies that either eliminate harmful self-reactive immune responses or bolster beneficial ones, such as anti-tumor immunity.
Researchers from Memorial Sloan Kettering Cancer Center used preclinical models of autoimmune type 1 diabetes and chronic viral infection to dissect the hierarchy of T cells within the so-called TCF1-high population. Although TCF1 has long been regarded as the signature transcription factor of stem-like T cells, the TCF1-high compartment is heterogeneous and not all cells within it are truly self-renewing.
The key discovery is that only a small fraction of TCF1-high T cells co-express the transcription factor LEF1, and this LEF1-positive subset constitutes the true stem T cell (TSC) pool. These cells follow a defined differentiation hierarchy: LEF1+ TSCs give rise to LEF1-negative TCF1-high progenitor T cells (TPRO), which lack stem functions and subsequently generate terminally differentiated TCF1-low T cells (TDIFF). LEF1 was found to be essential — not merely correlative — for this stemness capacity.
Strikingly, LEF1-positive T cells in both autoimmune and chronic infection settings share an epigenetically encoded core program enriched for genes characteristic of embryonic and adult stem cells, including active WNT/β-catenin and Notch signaling pathways. Spatial positioning within tissue niches, local signaling cues, and cell migration were all shown to regulate stem cell fate. Experimental targeting of integrins or Notch signaling impaired T cell stemness and reduced disease severity in animal models.
These findings reframe our understanding of immune memory and chronic disease biology. LEF1 and niche-derived signals are now actionable targets for conditions ranging from autoimmune diabetes to chronic viral infections and potentially cancer immunotherapy. Limitations include reliance on preclinical animal models and abstract-only access for full methodological review.
Key Findings
- LEF1 expression, not TCF1 alone, defines truly self-renewing stem T cells in chronic disease settings.
- T cells follow a hierarchy: LEF1+ stem cells → LEF1- progenitors → terminally differentiated cells.
- LEF1+ T cells share an epigenetic program with embryonic stem cells, including WNT and Notch pathways.
- Blocking integrin or Notch signaling disrupts T cell stemness and reduces disease in preclinical models.
- Findings apply across autoimmunity and chronic infection, suggesting a universal stemness mechanism.
Methodology
The study used preclinical mouse models of autoimmune type 1 diabetes and chronic viral infection to characterize T cell populations. Researchers employed transcriptional profiling, epigenetic analysis, and functional assays to define the LEF1+ stem T cell subset and its differentiation hierarchy. Spatial, niche-signaling, and migration experiments were used to test mechanistic hypotheses in vivo.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; methodological details and full datasets could not be reviewed. Findings are from preclinical animal models and require validation in human clinical studies before therapeutic translation. The precise niche factors and signals governing LEF1 expression in humans remain to be fully characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: